US heart group says COX 2 inhibitors should be last choice for pain relief in patients at risk
BMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39139.644664.DB (Published 01 March 2007) Cite this as: BMJ 2007;334:441- Susan Mayor
- London
Cyclo-oxygenase-2 (COX 2) inhibitors should be used only as the last choice after other types of non-steroidal anti-inflammatory drugs (NSAIDs) to relieve chronic pain in people with heart disease or at high risk of it, the American Heart Association has recommended. Its statement, which will be published this month in Circulation (http://circ.ahajournals.org), was designed to end any remaining confusion about the cardiovascular risk of these agents.
The association has recommended a stepped approach to treatment. The first step should be non-pharmacological approaches, such as physical therapy and weight loss, for patients with known cardiovascular disease or with risk factors for ischaemic heart disease. Drug treatment should start with agents with the lowest …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.